Ca-4-methyl-2-oxo-valerate (α-ketoanalogue to leucine, Ca salt) 101 mg, Ca-3-methyl-2-oxo-butyrate (α-ketoanalogue to valine, Ca salt) 86 mg, Ca-2-oxo-3-phenylpropionate (α-ketoanalogue to phenylalanine, Ca salt) 68 mg, Ca-3-methyl-2-oxo-valerate (α-ketoanalogue to isoleucine, Ca salt) 67 mg, Ca-DL-2-hydroxy-4-(methylthio) butyrate (α-hydroxyanalogue to methionine, Ca salt) 59 mg, L-lysine acetate 105 mg, L-threonine 53 mg, L-histidine 38 mg, L-tyrosine 30 mg, L-tryptophan 23 mg
Indications/Uses
Prevention & therapy of damages due to faulty or deficient protein metabolism in chronic renal insufficiency in connection w/ limited protein food of ≤40 g/day (for adults), ie, generally in patients w/ GFR <25 mL/min.
May lead to pathological increase of serum Ca level or intensification w/ medicaments containing Ca (eg, acetolyte). Reduce possible administration of Al hydroxide as uraemic symptoms improve. Reduction of serum phosphate. Interfered absorption w/ drugs that form sparingly soluble compd w/ Ca (eg, tetracyclines, quinolones (eg, ciprofloxacin, norfloxacin), Fe, fluoride, & estramustin-containing drugs). Susceptibility towards heart/cardio-active glycosides & hence, risk of arrhythmia increases w/ the rise of blood Ca conc.
Sign Out
